Trinity Net Current Asset Value from 2010 to 2026
| TRIB Stock | USD 0.80 0.09 12.68% |
Net Current Asset Value | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Total Revenue of 78.3 M or Gross Profit of 35 M, as well as many indicators such as Price To Sales Ratio of 1.4, Dividend Yield of 0.0019 or Days Sales Outstanding of 90.37. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
Trinity | Net Current Asset Value | Build AI portfolio with Trinity Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out the analysis of Trinity Biotech Correlation against competitors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Trinity Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.77) | Earnings Share (1.80) | Revenue Per Share | Quarterly Revenue Growth 0.181 | Return On Assets |
Trinity Biotech plc's market price often diverges from its book value, the accounting figure shown on Trinity's balance sheet. Smart investors calculate Trinity Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Trinity Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.